BullsEye Insights

BullsEye: Daily London AIM RNS Round-Up

Thursday 23 April 2020


Here is our summary of the day's hottest RNS alerts from across London's Alternative Investments Market (AIM).


Open Orphan Plc (ORPH.L)

Testing of anti-viral for treating COVID-19

Open Orphan plc the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, announced that its London-based subsidiary hVIVO has commenced the testing of an anti-viral for treating COVID-19 on behalf of its client Nearmedic International Ltd.


hVIVO has initiated work on this contract with Nearmedic International Ltd, a specialist pharmaceutical, biotechnological and medical business headquartered in Moscow, to test using hVIVO's virology expertise and laboratory capability an anti-viral drug with potential utility for treating SARS-CoV2 (COVID-19) infections. This drug has both potential anti-viral and anti-inflammatory activity and as such could reduce both virus infectivity and disease severity respectively.


hVIVO will be testing its utility against a panel of viruses to include influenza virus, "normal", circulating betacoronavirus and ultimately SARS-CoV2 (COVID-19).


For the full RNS, see: https://www.investegate.co.uk/open-orphan-plc/rns/testing-of-anti-viral-for-treating-covid-19/202004230700035708K/


Amryt Pharma Plc (AMYT.L)

EASE Study Enrollment Closed; Top Line Data Expected in Late Q3/Early Q4 2020

Amryt, a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases , today provided the following update with regard to its Global Phase 3 clinical study ("EASE") in Epidermolysis Bullosa ("EB").

EASE Trial Update:

In recent weeks, the COVID-19  pandemic has had a material impact on clinical trials globally, including patient recruitment. Given that the EASE study was already close to full enrollment, Amryt has taken advice from an independent expert and concluded that the statistical impact of further patient recruitment would most likely be negligible.  Amryt has therefore decided to close the EASE study to further enrollment.

Shortly after the last patient completes the end of the double-blind treatment period (Day 90), the study data will be cleaned and the database locked.  Statistical analyses will then be performed and the Company now anticipates top line data read out in late Q3 / early Q4 2020.


For full RNS details, see: https://www.investegate.co.uk/amryt-pharma-plc/rns/ease-clinical-study-update/202004230700035683K/


Ariana Resources Plc (AAU.L)

+25% increase over previous resource estimate and +72% increase over the Feasibility Study Resource

Ariana Resources plc, the AIM-listed exploration and development company operating in Europe, announced an update of its JORC compliant Mineral Resource Estimate for the Kiziltepe Mine.  Kiziltepe is part of the Red Rabbit Joint Venture with Proccea Construction Co. and is 50% owned by Ariana through its shareholding in Zenit Madencilik San. ve Tic. A.S.

Highlights:

  • Increase in global (undepleted) Mineral Resource Estimate to c. 321,000 oz gold (Au) and 5.03 Moz silver (Ag) contained metal on six main veins, including Kepez North and West.

  • Resource update represents a c. 25% increase over the previous resource estimate (announced in May 2017) and a c. 72% increase over the Feasibility Study resource, on an undepleted gold only basis. 

  • In-situ (depleted) Measured and Indicated Mineral Resource is 2.01Mt @ 2.51 g/t Au and 43.49 g/t Ag for 154,000 oz Au and 2.73 Moz Ag.

  • In-situ (depleted) Inferred Mineral Resource of a further 1.01Mt @ 2.23 g/t Au and 29.58 g/t Ag for 73,000 oz Au and 0.96 Moz Ag. 

  • Depletion to date includes 70,684 oz Au and 738,320 oz Ag produced from the Kiziltepe Mine to the end of Q1 2020, in addition to stockpiled ore (c. 130,000 t) awaiting processing.

  • Resource increase continues to support the potential for significantly extended mine life at Kiziltepe based on current throughput rates, should Resources be converted to Reserves. 

  • Several subsidiary veins comprise a substantial JORC Exploration Target which will be drill-tested in the future with the aim of converting to resources.


For full RNS details, see: https://www.investegate.co.uk/ariana-resources-plc/rns/significant-resource-update--kiziltepe/202004230700035637K/


Download the BullsEye app for your phone or tablet

AppStore.png
playstore.png

*tap here*